

Defining an international framework for pharmacy standards on oral anticoagulation

N. Hamed¹, C. Coleman², K. E. Hersberger³, N. Kristensen⁴, N. Kheir⁵, F. Van Mil⁶, B. J. van den Bemt⁷, S. Rydant⁸, S. Antoniou^{1,9} on behalf of the International Pharmacist for Anticoagulation Care Taskforce (iPACT)

1. Pharmacy, Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom,
2. School of Pharmacy, University of Connecticut, Connecticut, United States,
3. Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
4. Pharmacy, Apoteker, R, Lyngby, Denmark
5. College of Pharmacy, Qatar university, Doha, Qatar
6. Van Mil Consultancy, Zuidlaren
7. Pharmacy, Sint Maartenskliniek, 6574NA Ubbergen, Netherlands,
8. Pharmacy, Royal Association of Antwerp Pharmacists (KAVA), 2018 Antwerpen, Belgium,
9. Academic Health Science Network, UCLPartners, London, United Kingdom

Introduction

The identification and management of atrial fibrillation (AF) ensures patients at high risk of stroke are optimally protected to prevent an ischaemic stroke and access the best quality of anticoagulation practice. Pharmacists globally are in the perfect position to provide patients with a personalised package of care that encompasses the correct support, education, choice and adherence to oral anticoagulation treatment, while avoiding adverse related events.

However, a framework characterising the standards to optimally provide pharmaceutical care for patients receiving oral anticoagulation is lacking.

Objectives

Design and characterise a framework of international pharmacy standards for pharmaceutical care application on oral anticoagulation for prevention of AF related strokes.


Method

Stage 1: Design an international framework for pharmaceutical practice application and characterise specific standards with pharmacy practice dimensions



Stage 2: Present first draft to a working group during a workshop at international Pharmaceutical federation for discussion and feedback

Stage 3: Expert opinion consensus on the framework domains and standards using a Delphi method



Results

The framework consisted of thirteen overarching standards, which were defined and grouped into four domains (figure 1).

Figure 1. Pharmaceutical standards grouped into 4 domains.





Figure 2. Example of standards within the framework for pharmaceutical care application on oral anticoagulation for prevention of AF related strokes.



Discussion

A clearly defined framework of international standards has been developed as a clinical tool and quality assurance to optimise the delivery of care for oral anticoagulation in prevention of AF-related strokes. It will support pharmacists and their teams to develop their professional practice, improve services, and deliver safe and high quality patient care across all pharmacy settings. The framework is constructed with a uniform of standards that can be adapted if necessary in recognition to elements of anticoagulant care that may differ between countries.

Conclusion

This is the first international standard framework for pharmacy anticoagulation services that support the provision of high quality practice for local populations across the world.

Disclosure of interest

N. Hamed: Speaker's Bureau of Bayer, C. Coleman: None Declared, K. E. Hersberger: None Declared, N. Kristensen: None Declared, N. Kheir: None Declared, F. Van Mil: None Declared, B. J. van den Bemt: None Declared, S. Rydant: None Declared, S. Antoniou: Speaker's Bureau of Bayer, Boehringer Ingelheim, Daichi Sankyo, Pfizer/BMS

For further information contact:

Nadya Hamed, MRPharmS || Pharmacist for Cardiovascular Disease || Barts Health NHS Trust || St. Bartholomew's Hospital || Pharmacy Offices Basement - KVG Building, West Smithfield, London, EC1A 7BE, United Kingdom || Tel. 020 346 56419 || n.hamed@nhs.net